The deficiency of SOSTDC1 correlated with greater tumour size and treatment with recombinant SOSTDC1 effectively blocked WNT signalling components which contribute to cell proliferation, indicating its antagonistic role against Wnt pathway57. Here, SOSTDC1 is linked to neoplasm.